

GMP Compliance Menu

Search

[GMP Certificates](#)[Non-Compliance Report](#)[Print Preview](#)[Print Preview \(Short version\)](#)[Back To Search](#)**National Agency For The Safety Of Medicine And Health Products**

CERTIFICATE NUMBER : 2021/HPF/FR/014

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1), (2)**Part 1**

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer : **IPSEN PHARMA BIOTECH**

Site address : **Parc d'Activités du Plateau de Signes, Chemin départemental N° 402, SIGNES, 83870, France**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **M 20/144** in accordance with Art. 40 of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-11-06** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC (3)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

(1) The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

(2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

(3) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products
1 MANUFACTURING OPERATIONS
1.1 Sterile products
<p>1.1.1 Aseptically prepared (processing operations for the following dosage forms)</p> <p>1.1.1.2 Lyophilisates Special Requirements: 7 Other: hormones(en)</p> <p>1.1.1.4 Small volume liquids Special Requirements: 7 Other: cytotoxics(en)</p> <p>1.1.2 Terminally Sterilised (processing operations for the following dosage forms)</p> <p>1.1.2.2 Semi-solids Special Requirements: 7 Other: hormones(en)</p> <p>1.1.2.3 Small volume liquids Special Requirements: 7 Other: hormones(en)</p> <p>1.1.2.4 Solids and implants Special Requirements: 7 Other: hormones(en)</p> <p>1.1.3 Batch certification</p>
1.3 Biological medicinal products (list of product types)
<p>1.3.2 Batch Certification (list of product types)</p> <p>1.3.2.5 Biotechnology products</p>
1.5 Packaging
1.5.2 Secondary packaging
1.6 Quality control testing
<p>1.6.1 Microbiological: sterility</p> <p>1.6.2 Microbiological: non-sterility</p> <p>1.6.3 Chemical/Physical</p> <p>1.6.4 Biological</p>
2 IMPORTATION OF MEDICINAL PRODUCTS
2.1 Quality control testing of imported medicinal products
<p>2.1.1 Microbiological: sterility</p> <p>2.1.2 Microbiological: non-sterility</p> <p>2.1.3 Chemical/Physical</p> <p>2.1.4 Biological</p>
2.2 Batch certification of imported medicinal products
<p>2.2.1 Sterile products</p> <p>2.2.1.1 Aseptically prepared</p> <p>2.2.1.2 Terminally sterilised</p> <p>2.2.3 Biological medicinal products</p> <p>2.2.3.5 Biotechnology products</p>
2.3 Other importation activities
<p>2.3.1 Site of physical importation</p> <p>2.3.2 Importation of intermediate which undergoes further processing</p>

Clarifying remarks (for public users) :

Manufacture : The site is authorised to the parametric release of the only medicinal products whose marketing authorisation includes this operation. --- Signatory : Mr Said Ioughissen, deputy head of the pharmaceutical product inspection and counterfeiting fight department ---

The ANSM does not issue hard copies of good practice certificates.

2021-02-05

Name and signature of the authorised person of the Competent Authority of France

Confidential

National Agency For The Safety Of Medicine And Health Products

Tel : **Confidential**

Fax : **Confidential**

The EudraGMP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA. For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please [click here](#) to get list of NCA's.

Due to the restrictions caused by COVID-19, the period of validity of MIA's, WDA's, GMP and GDP certificates is automatically extended until the end of 2022, except where clarifying remarks in the document state otherwise. Manufacturers, importers and distributors must continue to comply with GMP/GDP and all other legal obligations. On-site inspections are conducted where and when possible. Competent authorities reserve the right to perform risk based supervision of sites by either on-site inspections or distant assessments and, based on the outcome, may continue to issue, withdraw or restrict GMP/GDP certificates, as appropriate

For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI.

Documents issued by UK authorities up to and including 31 December 2020 remain available for consultation in EudraGMP. However, they are no longer included or updated from 1 January 2021, with the exception of the documents pertaining to sites located in Northern Ireland.

[EMA © 2014. EudraGMP 6.4.9.9-covid-update build 2021/09/29 21:58]